GlassScriptPhysician profile
John T Fruth
NPI 1891197547
$7,438.39
in general payments reported to CMS, 2019-2025
26 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,932 · 2022: $1,427 · 2023: $1,412 · 2024: $1,124 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.35 |
| Education | $219.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,602.13 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,099.52 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $778.87 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $555.55 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $499.97 | 2021-2025 | Hyqvia, Cuvitru, Takhzyro |
| Biohaven Pharmaceuticals, INC. | $362.20 | 2021 | |
| Pfizer INC. | $277.05 | 2023-2025 | |
| Csl Behring | $252.91 | 2021-2025 | Hizentra, Haegarda |
| Teva Pharmaceuticals USA, INC. | $223.28 | 2021-2022 | |
| Lilly USA, LLC | $207.81 | 2021-2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.61 | 2021-2024 | Spiriva Respimat |
| Amgen INC. | $195.34 | 2021-2025 | Tezspire |
| Abbvie INC. | $193.78 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $189.82 | 2021-2025 | |
| Genentech USA, INC. | $143.57 | 2021-2025 | Xolair |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $142.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.07 | 2022 | |
| Biocryst US Sales Co., LLC | $67.56 | 2021 | |
| Grifols USA, LLC | $66.77 | 2022-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $47.11 | 2025 | Neffy |
| Incyte Corporation | $44.31 | 2021-2025 | Opzelura |
| Optinose US, INC. | $39.01 | 2022-2023 | |
| Octapharma USA, INC. | $38.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.82 | 2021 | |
| Uswm, LLC | $23.63 | 2021 | |
| Blueprint Medicines Corporation | $21.60 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fruth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.